Thrombectomy is the surgical removal of blood clot from a blood vessel. Venous thromboembolism (VTE) is a common lethal disease where blood clots within a vein. These clots can travel to arteries or veins in different parts of the body-brain, heart, kidneys, lungs, and limbs. VTE is considered as the cause of heart attack, stroke; however, it can also damage to the body’s organs or even death. VTE results due to various factors, which include combination of hereditary and acquired risk factors, obesity and post-surgery especially hip, knee, or pelvic surgery. It can be found in smoking population and people who take estrogens or birth control pills. VTE is most common in adults (>60 years) but can occur at any age.
The world thrombectomy devices market is estimated to garner $1,389 million by 2022. This is attributed by the increase in the incidence of acute myocardial infraction, peripheral arterial diseases, deep vein thrombosis, and pulmonary embolism due to the sedentary lifestyle, and unhealthy living conditions and habits in the current generation; rise in the geriatric population. The increase in incidence of cardiovascular diseases; growth in demand for minimally-invasive procedures, and demand for better healthcare infrastructure; and increase in competition, has led to technological advancements and innovations. However, lack of trained professionals and awareness, and complicated use of these devices restrict the market growth. In addition, deep vein thrombosis and pulmonary embolism sometimes remain underdiagnosed and can lead to serious health conditions, which can only be avoided by avoiding sedentary lifestyle and creating awareness among all.
The world thrombectomy devices market is segmented into five categories-technology, type, utility, disease, and geography. Based on the type of technology, the market is categorized into mechanical thrombectomy devices, aspiration thrombectomy devices, rheolytic thrombectomy devices. Based on type, the market is divided into automated devices and manual devices. Based on utility, the market is classified into reusable devices and disposable devices. The thrombectomy devices market is segmented into three disease categories, which include peripheral diseases, coronary diseases, and neuro diseases. Based on geography, the market is segmented into North America, Europe, Asia-Pacific, and LAMEA.
The growth in competition and continuous technological advancements have led to mergers & acquisitions by major players in the thrombectomy devices market. On September 2015, Medtronic acquired Lazarus Effect to strengthen its market of clot removal devices effective during ischemic stroke. Boston Scientific completed the acquisition of interventional business of Bayer AG on May 2014. This made Boston Scientific the leading innovator for peripheral vascular disease in the industry, and expanded their product portfolio and sales force across various geographies.
KEY MARKET BENEFITS:
The quantitative analysis of the current trends and future estimations from 2014 to 2022 is provided to identify the prevailing opportunities and formulate growth strategies.
In-depth analysis of the market based on geography gives an understanding of the regional market, which assists in strategic business planning.
A detailed analysis based on technology is presented to understand the type of products in trend or would be in demand to assist in product developments and collaborations.
Comprehensive analysis of the market drivers and constraints is provided to identify the prevailing market opportunities.
Competitive intelligence highlights the business practices followed by leading market players across various geographies.
Key market segments:
The world thrombectomy devices
MARKET SEGMENTATION is illustrated as follows:
Mechanical Thrombectomy Devices
Aspiration Thrombectomy Devices
Rheolytic Thrombectomy Devices
1.1 Report description
1.2 Key benefits
1.3 Key market segments
1.4 Research methodology
1.4.1 Secondary research
1.4.2 Primary research
1.4.3 Analyst tools and models
CHAPTER 2 EXECUTIVE SUMMARY
2.1 CXO perspective
CHAPTER 3 MARKET OVERVIEW
3.1 Market definition and scope
3.2 Key findings
3.2.1 Top investment pockets
3.2.2 Top winning strategies
3.3 Porters five forces analysis
3.3.1 Low bargaining power of suppliers
3.3.2 Moderate bargaining power of buyers
3.3.3 Moderate threat of new entrants
3.3.4 Moderate threat of substitutes
3.3.5 High competitive rivalry
3.4 Market dynamics
188.8.131.52 High prevalence of PAD, AMI, DVT & PE conditions
184.108.40.206 Rise in geriatric population
220.127.116.11 Growing demand of minimally invasive procedures
18.104.22.168 Better healthcare infrastructure
22.214.171.124 High competiton among key players
126.96.36.199 Lack of trained professionals and awareness
188.8.131.52 High cost and complicated use of thrombectomy devices
184.108.40.206 Introductin of lasers and uv radiation, and 3D imaging generation in thrombectomy devices
220.127.116.11 Combination of decompressive surgery and thrombectomy
CHAPTER 4 WORLD THROMBECTOMY DEVICES MARKET, BY TECHNOLOGY, 2014-2022
4.1.1 Market size and forecast
4.2 Mechanical thrombectomy devices
4.2.1 Key market trends
4.2.2 Key growth factors and opportunities
4.2.3 Market size and forecast
4.3 Aspiration thrombectomy devices
4.3.1 Key market trends
4.3.2 Key growth factors and opportunities
4.3.3 Market size and forecast
4.4 Rheolytic thrombectomy devices
4.4.1 Key market trends
4.4.2 Key growth factors and opportunities
4.4.3 Market size and forecast
CHAPTER 5 WORLD THROMBECTOMY DEVICES MARKET, BY TYPE, 2014-2022
5.1.1 Market size and forecast
5.2 Automated devices
5.2.1 Key market trends
5.2.2 Key growth factors and opportunities
5.2.3 Market size and forecast
5.3 Manual devices
5.3.1 Key market trends
5.3.2 Key growth factors and opportunities
5.3.3 Market size and forecast
CHAPTER 6 WORLD THROMBECTOMY DEVICES MARKET, BY UTILITY, 2014-2022
6.1.1 Market size and forecast
6.2 Reusable devices
6.2.1 Key market trends
6.2.2 Key growth factors and opportunities
6.2.3 Market size and forecast
6.3 Disposable devices
6.3.1 Key market trends
6.3.2 Key growth factors and opportunities
6.3.3 Market size and forecast
CHAPTER 7 WORLD THROMBECTOMY DEVICES MARKET, BY DISEASES, 2014-2022
7.1.1 Market size and forecast
7.2 Peripheral Diseases
7.2.1 Key market trends
7.2.2 Key growth factors and opportunities
7.2.3 Market size and forecast
7.3 Coronary Diseases
7.3.1 Key market trends
7.3.2 Key growth factors and opportunities
7.3.3 Market size and forecast
7.4 Neural Diseases
7.4.1 Key market trends
7.4.2 Key growth factors and opportunities
7.4.3 Market size and forecast
CHAPTER 8 WORLD THROMBECTOMY DEVICES MARKET, BY GEOGRAPHY, 2014-2022
8.1.1 Market size and forecast
8.2 North America
8.2.1 Key market trends
8.2.2 Key growth factors and opportunities
8.2.3 Market size and forecast
18.104.22.168 U.S. Market size and forecast
22.214.171.124 Canada Market size and forecast
126.96.36.199 Mexcio Market size and forecast
8.3.1 Key market trends
8.3.2 Key growth factors and opportunities
8.3.3 Market size and forecast
188.8.131.52 Germany Market Size And Forecast
184.108.40.206 France Market Size And Forecast
220.127.116.11 U.K. Market Size And Forecast
18.104.22.168 Italy Market Size And Forecast
22.214.171.124 Spain Market Size And Forecast
126.96.36.199 Rest Of Europe Market Size And Forecast
8.4.1 Key market trends
8.4.2 Key growth factors and opportunities
8.4.3 Market size and forecast
188.8.131.52 Japan Market size and forecast
184.108.40.206 China Market size and forecast
220.127.116.11 India Market size and forecast
18.104.22.168 Rest of Asia-Pacific Market size and forecast
8.5 Latin America, Middle East, Africa (LAMEA)
8.5.1 Key market trends
8.5.2 Key growth factors and opportunities
8.5.3 Market size and forecast
22.214.171.124 Brazil Market size and forecast
126.96.36.199 Saudi Arabia Market size and forecast
188.8.131.52 South Africa Market size and forecast
184.108.40.206 Rest of lamea Market size and forecast
CHAPTER 9 COMPANY PROFILES
9.1 Boston Scientific Corporation
9.1.1 Company overview
9.1.2 Company snapshot
9.1.3 Operating business segments
9.1.4 Business performance
9.1.5 Key strategic moves & developments
9.2 Medtronic Plc
9.2.1 Company overview
9.2.2 Company snapshot
9.2.3 Operating business segments
9.2.4 Business performance
9.2.5 Key strategic moves & developments
9.3 Teleflex Incorporated
9.3.1 Company overview
9.3.2 Company snapshot
9.3.3 Operating business segments
9.3.4 Business performance
9.3.5 Key strategic moves & developments
9.4 Terumo Corporation
9.4.1 Company overview
9.4.2 Company snapshot
9.4.3 Operating business segments
9.4.4 Business performance
9.4.5 Key strategic moves & developments
9.5 Penumbra, Inc.
9.5.1 Company overview
9.5.2 Company snapshot
9.5.3 Operating business segments
9.5.4 Business performance
9.5.5 Key strategic moves & developments
9.6 The Spectranetics Corporation
9.6.1 Company overview
9.6.2 Company snapshot
9.6.3 Operating business segments
9.6.4 Business performance
9.6.5 Key strategic moves & developments
9.7 AngioDynamics, Inc.
9.7.1 Company overview
9.7.2 Company snapshot
9.7.3 Operating business segments
9.7.4 Business performance
9.7.5 Key strategic moves & developments
9.8 Vascular Solutions, Inc.
9.8.1 Company overview
9.8.2 Company snapshot
9.8.3 Operating business segments
9.8.4 Business performance
9.8.5 Key strategic moves & developments
9.9 Johnson & Johnson, Inc.
9.9.1 Company overview
9.9.2 Company snapshot
9.9.3 Operating business segments
9.9.4 Business performance
9.9.5 Key strategic moves & developments
9.10 Stryker Corporation
9.10.1 Company Overview
9.10.2 Company Snapshot
9.10.3 Operating business segments
9.10.4 Business performance
9.10.5 Key strategic moves & developments
High occurrences of acute myocardial infarction, peripheral artery disease, deep vein thrombosis, VTE (Venous Thromboembolism) and pulmonary embolism owing to the sedentary, and unhealthy lifestyle majorly drives the market growth. VTE is most common in adults (>60 years). In addition, better healthcare infrastructure and increase in demand for minimally-invasive treatments; rise in the geriatric population, which increases incidence of cardiovascular diseases; and technological advancements & innovations are the factors that nurture the growth of the thrombectomy devices market. Some of the restraints associated with the thrombectomy devices market are scarcity of trained professionals, lack of awareness, and the complicated use of devices.
Disposable thrombectomy devices segment generated highest revenue in 2015 and would continue to follow this trend throughout the analysis period.
Geographically, North America occupied a major market share in 2015, and is expected to continue leading during analysis period. This was attributed to the sedentary and unhealthy lifestyle of the current generation, demand of better healthcare infrastructure, and increase in demand for minimally-invasive treatments and incidence of cardiovascular diseases. However, Asia-Pacific followed by LAMEA are expected to be the fastest growing regions, owing to the presence of ample growth opportunities in terms of unmet medical needs for the treatment of thrombus.
The thrombectomy devices market holds a substantial scope for growth globally. Recent innovations, which embed introduction of innovative ideas such as use of lasers, ultraviolet radiation, and 3D image generation, will provide better results to the physicians and allow them to work more efficiently. The upcoming trend in this market is the introduction of a technique, which involves the combination of decompressive hemicraniectomy and endovascular thrombectomy to treat patients with cerebral venous thrombosis.
Key findings of the Thrombectomy Devices Market
Mechanical thrombectomy devices was the leading segment in 2015, and is expected to maintain this position throughout the analysis period.
Neurovascular disorder is the major indication which uses thrombectomy devices for treatment; with over half of the total market share in 2015.
Peripheral and coronary diseases segments are projected to grow at a significant CAGR.
Reusable thrombectomy devices is projected to grow at a CAGR of 7.7%.
U.S market for thrombectomy devices is projected to grow at a CAGR of 5.0%.
U.S. was the largest country market in 2015, and is projected to maintain its lead until 2022.
Key players have adopted mergers & acquisitions and product launch as their key strategies in the thrombectomy devices market. This is due to the growth in competition and continuous technological advancements. In July, 2016, Penumbra launched thrombectomy device ACE 68 Reperfusion Catheter for commercial use in the U.S. This catheter uses the latest advancements available in the tracking technology and delivers maximum aspiration power for extracting thrombus in stroke intervention. This product launch is expected to strengthen the product portfolio of Penumbra, a leading market player. The major market players profiled in this report include Boston Scientific Corporation, Medtronic Plc, Teleflex Incorporated, Penumbra Inc., The Spectranetics Corporation, AngioDynamics, Inc., Terumo Corporation, Johnson and Johnson, Inc., Stryker Corporation, and Vascular Solutions, Inc.
The Spectranetics Corporation
Johnson and Johnson, Inc.
Vascular Solutions, Inc.